214 related articles for article (PubMed ID: 17998935)
1. HIF alpha expression in VHL-deficient renal cancer cells is dependent on phospholipase D.
Toschi A; Edelstein J; Rockwell P; Ohh M; Foster DA
Oncogene; 2008 Apr; 27(19):2746-53. PubMed ID: 17998935
[TBL] [Abstract][Full Text] [Related]
2. Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.
Sourbier C; Srivastava G; Ghosh MC; Ghosh S; Yang Y; Gupta G; Degraff W; Krishna MC; Mitchell JB; Rouault TA; Linehan WM
Oncotarget; 2012 Nov; 3(11):1472-82. PubMed ID: 23178531
[TBL] [Abstract][Full Text] [Related]
3. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
4. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.
Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO
Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846
[TBL] [Abstract][Full Text] [Related]
5. NF-kappaB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas.
Pantuck AJ; An J; Liu H; Rettig MB
Cancer Res; 2010 Jan; 70(2):752-61. PubMed ID: 20068166
[TBL] [Abstract][Full Text] [Related]
6. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
7. Formation of Renal Cysts and Tumors in Vhl/Trp53-Deficient Mice Requires HIF1α and HIF2α.
Schönenberger D; Harlander S; Rajski M; Jacobs RA; Lundby AK; Adlesic M; Hejhal T; Wild PJ; Lundby C; Frew IJ
Cancer Res; 2016 Apr; 76(7):2025-36. PubMed ID: 26759234
[TBL] [Abstract][Full Text] [Related]
8. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
9. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma.
Turcotte S; Desrosiers RR; Beliveau R
Am J Physiol Renal Physiol; 2004 Feb; 286(2):F338-48. PubMed ID: 14583436
[TBL] [Abstract][Full Text] [Related]
11. Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas.
Cuevas Y; Hernández-Alcoceba R; Aragones J; Naranjo-Suárez S; Castellanos MC; Esteban MA; Martín-Puig S; Landazuri MO; del Peso L
Cancer Res; 2003 Oct; 63(20):6877-84. PubMed ID: 14583486
[TBL] [Abstract][Full Text] [Related]
12. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.
Thompson JM; Nguyen QH; Singh M; Pavesic MW; Nesterenko I; Nelson LJ; Liao AC; Razorenova OV
Oncogene; 2017 Feb; 36(8):1080-1089. PubMed ID: 27841867
[TBL] [Abstract][Full Text] [Related]
13. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.
Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S
Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597
[TBL] [Abstract][Full Text] [Related]
14. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.
Carroll VA; Ashcroft M
Cancer Res; 2006 Jun; 66(12):6264-70. PubMed ID: 16778202
[TBL] [Abstract][Full Text] [Related]
15. Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma.
Luu VD; Boysen G; Struckmann K; Casagrande S; von Teichman A; Wild PJ; Sulser T; Schraml P; Moch H
Clin Cancer Res; 2009 May; 15(10):3297-304. PubMed ID: 19401348
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
Rathmell WK; Hickey MM; Bezman NA; Chmielecki CA; Carraway NC; Simon MC
Cancer Res; 2004 Dec; 64(23):8595-603. PubMed ID: 15574766
[TBL] [Abstract][Full Text] [Related]
17. VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations.
Rechsteiner MP; von Teichman A; Nowicka A; Sulser T; Schraml P; Moch H
Cancer Res; 2011 Aug; 71(16):5500-11. PubMed ID: 21715564
[TBL] [Abstract][Full Text] [Related]
18. [Tumor suppressor gene VHL, hypoxia inducible factor, and renal cell carcinoma].
Zhang YT; Chen N; Zeng H; Zhou Q
Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):562-4. PubMed ID: 17134554
[No Abstract] [Full Text] [Related]
19. PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma.
Ruf M; Moch H; Schraml P
Int J Cancer; 2016 Jul; 139(2):396-403. PubMed ID: 26945902
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
Liu MY; Poellinger L; Walker CL
Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]